Abstract: Provided herein are methods and systems for the simultaneous targeted detection and sequencing of DNA, RNA, and Protein. In typical embodiments, the DNA, RNA, and Proteins are detected, characterized, and sequenced using just a single mammalian cell. One embodiment of detecting and characterizing DNA, RNA, or protein from a mammalian cell includes encapsulating a single cell in a drop and performing a protease digest on the encapsulated cell drop, performing a reverse transcriptase reaction; performing a droplet merger with barcoding PCR reagents and barcoding beads; performing a PCR reaction to attach the cell barcodes to the DNA targeted amplicons, RNA targeted amplicons, and protein tag amplicons, where all amplicons from the same emulsion contain the same cell barcode; and detecting and characterizing a DNA, RNA, or protein amplicon by sequencing the cell barcode incorporated into each amplicon.

Abstract: A method for spatially tagging nucleic acids of a biological specimen, including steps of (a) providing a solid support comprising different nucleic acid probes that are randomly located on the solid support, wherein the different nucleic acid probes each includes a barcode sequence that differs from the barcode sequence of other randomly located probes on the solid support; (b) performing a nucleic acid detection reaction on the solid support to locate the barcode sequences on the solid support; (c) contacting a biological specimen with the solid support that has the randomly located probes; (d) hybridizing the randomly located probes to target nucleic acids from portions of the biological specimen; and (e) modifying the randomly located probes that are hybridized to the target nucleic acids, thereby producing modified probes that include the barcode sequences and a target specific modification, thereby spatially tagging the nucleic acids of the biological specimen.

Abstract: A method for supercoiling DNA, e.g. negatively supercoiling DNA, is disclosed. In an initial state, at least part of a DNA molecule is torsionally constrained and associated with a first linking number. The at least part of the DNA molecule has a first end connected to a first body and a second end connected to a second body. The method comprises increasing a distance between the first body and the second body for inducing a torque in the at least part of the DNA molecule and for bringing the at least part of the DNA molecule from the initial state into an intermediate state. In the intermediate state the at least part of the DNA molecule is temporarily torsionally unconstrained for at least partially releasing the induced torque for changing, e.g. decreasing, the first linking number.

Abstract: The invention relates to methods of detecting nucleic acids, including methods of detecting one or more target nucleic acid sequences in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support or suspending cells are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. The invention further relates to methods to improve probe hybridization specificity and their application in genotyping. The invention also relates to in situ detection of mis-joined nucleic acid sequences. The invention relates to reducing false positive signals and improve signal-to-background ratio in hybridization-based nucleic acid detection assay. The invention further relates to method to improve specificity in hybridization based nucleic acid using co-location probes. Compositions, tissue slides, sample of suspended cells, kits, and systems related to the methods are also described.

Abstract: Methods are provided for reducing the complexity of a population of nucleic acids prior to performing an analysis of the nucleic acids, e.g., sequence analysis. The methods result in a subset of the initial population enriched for a target region, which is typically located within one or more target fragments. The methods are particularly useful for analyzing populations having a high degree of complexity, e.g., chromosomal-derived DNA, whole genomic DNA, or mRNA populations.

Abstract: The disclosure provides methods, compositions, systems, and kits for the concurrent detection and analysis of different structural and chemical forms of nucleic acids in a sample.

Abstract: The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3?-OH blocking group covalently attached thereto, such that the 3? carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R?)2-O—R?, —C(R?)2-N(R?)2, —C(R?)2-N(H)R?, —C(R?)2-S—R? and —C(R?)2-F, wherein each R? is or is part of a removable protecting group; each R? is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R?)2 represents an alkylidene group of formula ?C(R??)2 wherein each R?? may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R? is exchanged for H or, where Z is —C(R?)2-F, the F is ex

Abstract: The disclosure provides a nanopore system assembled with non-membrane proteins for detecting analytes. Also disclosed are the methods, kits, and detection devices employing the disclosed nanopore system. The nanopore system has a wide variety of applications, including single molecule detection, DNA/RNA/peptide sequencing, sensing of chemicals, biological reagents, and polymers, and disease diagnosis.

Abstract: A method of labelling a nucleic acid of interest (NAOI) is provided. In some embodiments, the method may comprise contacting a sample comprising the nucleic acid of interest with a pool of oligonucleotides, the pool comprising oligonucleotides having at least 5 different lengths; and attaching an oligonucleotide from the pool on to one or each end of the nucleic acid of interest, wherein attachment of an oligonucleotide moves the read start and/or stop coordinate when the labelled NAOI is sequenced.

Abstract: The invention provides methods and kits for ordering sequence information derived from one or more target polynucleotides. In one aspect, one or more tiers or levels of fragmentation and aliquoting are generated, after which sequence information is obtained from fragments in a final level or tier. Each fragment in such final tier is from a particular aliquot, which, in turn, is from a particular aliquot of a prior tier, and so on. For every fragment of an aliquot in the final tier, the aliquots from which it was derived at every prior tier is known, or can be discerned. Thus, identical sequences from overlapping fragments from different aliquots can be distinguished and grouped as being derived from the same or different fragments from prior tiers. When the fragments in the final tier are sequenced, overlapping sequence regions of fragments in different aliquots are used to register the fragments so that non-overlapping regions are ordered.

Abstract: This disclosure provides oligomers, combinations of oligomers, compositions, kits, uses, and methods for detecting a C1orf43 nucleic acid, such as C1orf43 mRNA, such as human C1orf43 mRNA, in a sample.

Abstract: Provided are compositions and methods for detecting a target DNA (double stranded or single stranded) in a sample. In some embodiments, a subject method includes: (a) contacting the sample with: (i) a type V CRISPR/Cas effector protein (e.g., a Cas12 protein such as Cas12a, Cas12b, Cas12c, Cas12d, Cas12e); (ii) a guide RNA (comprising a region that binds to the type V CRISPR/Cas effector protein, and a guide sequence that hybridizes with the target DNA); and (iii) a detector DNA that is single stranded (i.e., a “single stranded detector DNA”) and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage (by the type V CRISPR/Cas effector protein) of the single stranded detector DNA. Also provided are compositions and methods for cleaving single stranded DNAs (e.g., non-target ssDNAs), e.g., inside of a cell.

Abstract: Methods and kits for predicting the response of a subject to an anti-TNF? therapy, in high accuracy, are provided.

Abstract: Disclosed herein is a method of performing polymerase chain reaction (PCR) to determine a repeating number of CGG sequence in fragile X mental retardation 1 (FMR1) gene. Also disclosed herein are a kit, and uses thereof in making a diagnosis of Fragile X syndrome (FXS) in a human subject based on the repeating number of the CGG sequence in a DNA sample isolated from the human subject. According to embodiments of the present disclosure, the kit comprises four primers, in which the first primer comprises a first polynucleotide sequence of SEQ ID NO: 1; the second primer comprises a second polynucleotide sequence of SEQ ID NO: 2; the third primer comprises a third polynucleotide sequence of SEQ ID NO: 3, and a non-human sequence disposed at and connected to the 5?-end of the third polynucleotide sequence; and the fourth primer comprises the non-human sequence.

Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA.

Abstract: A method for verifying a genomic variant region in an embryo, is disclosed. Embryo sequencing data is received by one or more processors. The received embryo sequencing data is aligned to a reference genome, by the one or more processors. A genomic variant region is identified in the aligned embryo sequencing data, by the one or more processors. A number of single nucleotide variants (SNVs) is counted in the identified genomic variant region, by the one or more processors. The counted number of SNVs in the identified genomic variant region is normalized against a baseline count of SNVs for a reference region corresponding to the identified genomic variant region to generate a normalized SNV density for the genomic variant region, by the one or more processors. The identified genomic variant region is verified, by the one or more processors, if the normalized SNV density in the identified genomic variant region satisfies a tolerance criterion.

Abstract: Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject. The methods include detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection. The methods include detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T brucei (such as T. brucei brucei, T b. rhodesiense, or T b. gambiense). The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and/or a deletion of N388 and Y389 to the subject.

Abstract: The present invention provides prognostic, predictive, and therapeutic methods for the treatment of rheumatoid arthritis (RA). The invention is based, at least in part, on the discovery that the expression level of one or more biomarkers described herein in a sample (e.g., a synovial tissue sample, a synovial fluid sample, or a combination thereof) from an individual having RA can be used in methods of determining whether an individual having RA is likely to exhibit disease progression, identifying an individual having RA who is likely to respond to a treatment including a disease modifying anti-rheumatic drug (DMARD), predicting responsiveness of an individual having RA to a treatment including a DMARD, selecting a therapy for an individual having RA, and treating an individual having RA, as well as related kits.

Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.

Abstract: The present invention generally relates to the field of cancer, in particular to cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency. Examples of such cancers include many colorectal, gastric, and endometrial tumors. Accordingly, the present invention provides a novel diagnostic marker panel for analyzing MSI loci, together with methods and kits of using said panel in the detection of cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency.

Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.

Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (?15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.

Abstract: Disclosed is a method for in vitro predicting the outcome of an individual having a multiple myeloma, including: -a) measuring the expression level of at least 2 genes encoding a ROS detoxifying (AOX) protein selected in a group including AKR1 B1, ARNT, CAT, CBR DHCR24, EGLN1, GLRX2, HIF1A, MGST1, MSRB1, PRDX6, SLC7A1 1, SOD1, SRXN1, TALDO1 and TXN and/or the expression level of at least 2 genes encoding ROS producing (ROS) protein selected in a group including CYBA, CYB5A, CYC1, NCF1 B, NCF1 C, NCF4, NDUFA12, NDUFS2, NDUFS8, SHC1 and UQCR10, in a biological sample obtained from the individual; -b) calculating an AOX score value and/or a ROS score value from the respective expression level(s) obtained at step a); -c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.

Abstract: The present disclosure provides methods for the identification of tumor-specific isoforms of polymorphic gene expression products. Methods of using said isoforms in the diagnosis and/or treatment of cancers and neoplasias are also provided.

Abstract: The invention is a method of predicting response to therapy in a cancer patient by serial sampling the patient's cell-free tumor nucleic acids to determine a change in the number of mutations per amount of plasma.

Abstract: Provided herein are probe and primer pairs that are useful for the detection of HPV in samples isolated from patients.

Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Abstract: Disclosed herein are methods for assaying a biological sample from a subject by analyzing components of microvesicle fractions in aid of risk, diagnosis, prognosis or monitoring of, or directing treatment of the subject for, a disease or other medical condition in the subject. Also disclosed are methods of treatment and identifying biomarkers using a microvesicle fraction of a subject. Kits, pharmaceutical compositions, and profiles related to the methods are also disclosed.

Abstract: Methods for the rapid detection of the presence or absence of Babesia in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting Babesia and kits are provided that are designed for the detection of Babesia, including, but not limited to, the Babesia species of B. microti, B. divergens, B. duncani, and B. venatorum. Also described are kits, reaction mixtures, and oligonucleotides (e.g., primer and probe) for the amplification and detection of Babesia.

Abstract: Methods for the rapid detection of the presence or absence of Babesia in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting Babesia and kits are provided that are designed for the detection of Babesia, including, but not limited to, the Babesia species of B. microti, B. divergens, B. duncani, and B. venatorum. Also described are kits, reaction mixtures, and oligonucleotides (e.g., primer and probe) for the amplification and detection of Babesia.

Abstract: Nucleic acid sequences for predicting and controlling shell phenotype in palm.

Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.

Abstract: The invention provides systems and methods for analyzing viruses by representing viral genetic diversity with a directed acyclic graph (DAG), which allows genetic sequencing technology to detect rare variations and represent otherwise difficult-to-document diversity within a sample. Additionally, a host-specific sequence DAG can be used to effectively segregate viral nucleic acid sequence reads from host sequence reads when a sample from a host is subject to sequencing. Known viral genomes can be represented using a viral reference DAG and the viral sequence reads from the sample can be compared to viral DAG to identify viral species or strains from which the reads were derived. Where the viral sequence reads indicate great genetic diversity in the virus that was infecting the host, those reads can be assembled into a DAG that itself properly represents that diversity.

Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Hepatitis E Virus (HEV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

Abstract: The present invention relates to a newly isolated bacterium belonging to the genus Microbacterium, a composition for producing psicose comprising the strain, and a method for producing psicose using the same.

Abstract: The disclosure provides a system for production of reactive intermediates from lignocellulosic biomass. The reactive intermediates can be used as platform chemicals for biological conversions or can be further catalytically upgraded to be used as “drop in” reagents for fuels. The disclosure provides methods and compositions useful for processing biomass to biofuels and intermediates.

Abstract: Bag house dust is combined with a carbon source and shaped into pellets or briquettes and used to recycle valuable metals present in the bag house dust.

Abstract: An inoculant for the manufacture of cast iron with spheroidal graphite is disclosed, the inoculant has a particulate ferrosilicon alloy having between 40 and 80% by weight of Si, 0.02-8% by weight of Ca; 0-5% by weight of Sr; 0-12% by weight of Ba; 0-10% by weight of rare earth metal; 0-5% by weight of Mg; 0.05-5% by weight of Al; 0-10% by weight of Mn; 0-10% by weight of Ti; 0-10% by weight of Zr; the balance being Fe and incidental impurities in the ordinary amount, wherein the inoculant additionally contains, by weight, based on the total weight of inoculant: 0.1 to 15% by weight of particulate rare earth metal oxide(s) and at least one of from 0.1 to 15% of particulate Bi2O3, and/or from 0.1 to 15% of particulate Bi2S3, and/or from 0.1 to 15% of particulate Sb2O3, and/or from 0.1 to 15% of particulate Sb2S3, and/or from 0.1 to 5% of one of more of particulate Fe3O4, Fe2O3, FeO, or a mixture thereof, and/or from 0.

Abstract: An inoculant for the manufacture of cast iron with spheroidal graphite is disclosed, the inoculant has a particulate ferrosilicon alloy having between 40 and 80% by weight of Si; 0.02-8% by weight of Ca; 0-5% by weight of Sr; 0-12% by weight of Ba; 0-15% by weight of rare earth metal; 0-5% by weight of Mg; 0.05-5% by weight of Al; 0-10% by weight of Mn; 0-10% by weight of Ti; 0-10 by weight of Zr; the balance being Fe and incidental impurities in the ordinary amount, wherein the inoculant additionally contains, by weight, based on the total weight of inoculant: 0.1 to 15% of particulate Sb2S3, and optionally between 0.1 and 15% of particulate Bi2O3, and/or between 0.1 and 15% of particulate Sb2O3, and/or between 0.1 and 15% of particulate Bi2S3, and/or between 0.1 and 5% of one or more of particulate Fe3O4, Fe2O3, FeO, or a mixture thereof, and/or between 0.1 and 5% of one or more of particulate FeS, FeS2, Fe3S4, or a mixture thereof, a method for producing such inoculant and use of such inoculant.

Abstract: An inoculant for the manufacture of cast iron with spheroidal graphite is disclosed, the inoculant has a particulate ferrosilicon alloy having between 40 and 80% by weight of Si; 0.02-8% by weight of Ca; 0-5% by weight of Sr; 0-12% by weight of Ba; 0-15% by weight of rare earth metal; 0-5% by weight of Mg; 0.05-5% by weight of Al; 0-10% by weight of Mn; 0-10% by weight of Ti; 0-10 by weight of Zr; the balance being Fe and incidental impurities in the ordinary amount, wherein the inoculant additionally contains, by weight, based on the total weight of inoculant: 0.1 to 15% of particulate Sb2S3, and optionally between 0.1 and 15% of particulate Bi2O3, and/or between 0.1 and 15% of particulate Sb2O3, and/or between 0.1 and 15% of particulate Bi2S3, and/or between 0.1 and 5% of one or more of particulate Fe3O4, Fe2O3, FeO, or a mixture thereof, and/or between 0.1 and 5% of one or more of particulate FeS, FeS2, Fe3S4, or a mixture thereof, a method for producing such inoculant and use of such inoculant.

Abstract: A flat product of steel with yield strength ftp 0.2 of 660 to 820 MPa, BH2 value greater than 30 MPa, a hole expansion ratio greater than 30%, and a microstructure having a first main component at a proportion of at least 50%, including one or more individual components of ferrite, tempered bainite, and tempered martensite, each with less than 5% carbides, and a second main component at a proportion of 5% to 50%, including one or more individual components of martensite, residual austenite, bainite or perlite, with the steel having a following chemical composition (in weight %): C: 0.04 to 0.12; Si: 0.03 to 0.8; Mn: 1 to 2.5: P: max. 0.08; S: max. 0.01; N: max. 0.01; Al: up to 0.1; Ni+Mo; up to 0.5; Nb: up to 0.08; Ti: up to 0.2; Nb+Ti: min, 0.03; Cr: up to 0.6; the remainder being iron including unavoidable steel-associated elements.

Abstract: The invention discloses a continuous hot rolled coil for a high collapse-resistant SEW petroleum casing and a manufacturing method thereof, and belongs to the technical field of hot continuous rolling production. Provided is a continuous hot rolled coil for a high collapse-resistant SEW petroleum casing with low alloy element cost and excellent initial welding property, and a manufacturing method thereof. The production cost of the hot continuous rolled coil is lowered by reducing expensive alloy elements such as Mo and V therein, and strictly controlling the content components of chemical elements such as Cr, Mn and Ti.

Abstract: A high strength steel sheet including, by weight, C: 0.001% to 0.004%, Si: 0.5% or less (excluding 0%), Mn: 1.2% or less (excluding 0%), P: 0.005% to 0.12%, S: 0.01% or less, N: 0.01% or less, acid soluble Al: 0.1% or less (excluding 0%), Ti: 0.01% to 0.04%, a remainder of Fe, and unavoidable impurities, wherein the contents of Ti, N, and S satisfy the following Relationship 1, a ratio (b/a) of an average random intensity ratio (b) of an orientation group of (111) [1-10] to (111) [?1-12] to an average random intensity ratio (a) of an orientation group of (001) [1-10] to (110) [1-10] at a point t/4 (where t is a thickness of the steel sheet) in a thickness direction of the steel sheet is 2.3 or more, and a bake hardenability (BH) of the steel sheet is 4 MPa or more.

Abstract: A cold rolled steel sheet of the present invention has a specific chemical composition and a steel microstructure in which the average aspect ratio of ferrite crystal grains is 2.0 or less; an rave value that is the average value of values obtained by measuring the r-value represented by a first predetermined formula in three places apart with spacings of 200 mm in the sheet width direction is 1.20 or more, and |?rave| that is the average value of values obtained by measuring, in three places apart with spacings of 200 mm in the sheet width direction, |?r| that is the absolute value of ?r represented by a second predetermined formula is 0.40 or less and the difference between the largest value and the smallest value of |?r| among the three places is 0.15 or less.

Abstract: A non-oriented electrical steel sheet includes a silicon steel sheet and an insulation coating. When t is a thickness of the silicon steel sheet and when PDR is defined as (PDR=(maximum?minimum)/minimum×100) which indicates a ratio concerned with maximum and minimum of number densities of AlN precipitates in three areas which are 1/10t area, ?t area, and ½t area from a surface of the silicon steel sheet along a thickness direction, the PDR is 50% or less.

Abstract: A grain-oriented electrical steel sheet includes: a silicon steel sheet including Si and Mn; a glass film arranged on a surface of the silicon steel sheet; and an insulation coating arranged on a surface of the glass film, wherein the glass film includes a Mn-containing oxide.

Abstract: A method is for manufacturing a high-strength steel sheet having a tensile strength of more than 1100 MPa and a yield strength of more than 700 MPa, a uniform elongation UE of at least 8.0% and a total elongation of at least 10%, made of a steel containing in percent by weight: 0.1%?C?0.25%, 4.5%?Mn?10%, 1%?Si?3%, 0.03%?Al?2.5%, the remainder being Fe and impurities resulting from the smelting, the composition being such that CMnIndex=C×(1+Mn/3.5)?0.6. The method includes annealing a rolled sheet made of said steel by soaking it at an annealing temperature TA higher than the Ac1 transformation point of the steel but less than 1000° C., cooling the annealed sheet to a quenching temperature QT between 190° C. and 80° C. at a cooling speed sufficient to obtain a structure just after cooling containing martensite and retained austenite, maintaining the steel sheet at an overaging temperature PT between 350° C. and 500° C. for an overaging time Pt of more than 5 s cooling the sheet down to the ambient temperature.

Abstract: A process for manufacturing a non-stamped prealloyed steel coil, sheet or blank, comprising the following successive steps of: providing a non-stamped precoated steel coil, sheet or blank composed of a steel substrate covered by a precoating of aluminum, or aluminum-based alloy, or aluminum alloy, wherein the precoating thickness is comprised between 10 and 35 micrometers on each side of the steel coil, sheet or blank, then heating the non-stamped steel coil, sheet or blank in a furnace under an atmosphere containing at least 5% oxygen, up to a temperature ?1 comprised between 750 and 1000° C., for a duration t1 comprised between t1min and t1max, wherein: t1min=23500/(?1?729.5) and t1max=4.946×1041×?1?13.08, t1 designating the total duration in the furnace, ?1 being expressed in ° C.

Abstract: Apparatus and methods for lithium extraction from aqueous sources are described herein. Divalent ions are removed using staged membrane separation. The aqueous source is subjected to a solvent extraction process that extracts lithium. Aqueous and organic phases of streams produced by the solvent extraction process are separated using electrical and/or gas flotation separation. The solvent is de-complexed to unload lithium. Streams produced by the de-complexing may be subjected to electrical and/or gas flotation separation. Solvent de-complexing can be performed using an electrical separator. Aqueous streams are pH adjusted for return to the environment.